Greeve J, Axelos D, Welker S, Schipper M, Greten H
Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany.
Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1079-92. doi: 10.1161/01.atv.18.7.1079.
The expression of apolipoprotein (apo) B can be modulated by mRNA editing, a unique posttranscriptional base change in the apo B mRNA. Apo B-48, the translation product of edited apo B mRNA, is not a precursor of the atherogenic low density lipoproteins and lipoprotein(a). In humans and various other mammals, the apo B mRNA is edited in the intestine but not in the liver, which exclusively secretes apo B-100-containing lipoproteins as precursors for low density lipoprotein formation. In species such as the rat, mouse, dog, and horse, apo B mRNA is also edited in the liver, resulting in low plasma levels of low density lipoprotein. Editing of the apo B mRNA is mediated by the apo B mRNA-editing enzyme complex, of which the catalytic subunit APOBEC-1 is not expressed in the liver of species without hepatic editing. To understand the molecular basis for liver-specific expression of APOBEC-1 and the editing of hepatic apo B mRNA, the expression pattern and genomic organization of the rat APOBEC-1 gene have been characterized. The rat APOBEC-1 gene contains 6 exons and 2 promoters with distinct activities. The expression of APOBEC-1 in the rat liver is the result of a promoter located upstream, with tissue-specific exon use and alternate splicing within the 5'-untranslated region of APOBEC-1 mRNA encoded by exon 2. In addition to the liver, this promoter also induces APOBEC-1 expression in the spleen, lung, kidney, heart, and skeletal muscle. The promoter located downstream belongs to a new class of TATA-less promoters and is responsible for the abundant expression of APOBEC-1 in the intestine. Mapping of the transcriptional start sites and deletion analysis of the promoter regions by using luciferase as the reporter gene have defined the regulatory elements of both promoters. The downstream, intestine-specific promoter contains a negative regulatory element between -1100 and -500, which appears to restrict its activity to the intestine. The upstream, liver-specific promoter of the rat APOBEC-1 gene induces APOBEC-1 expression and editing of apo B mRNA in human hepatoma HuH-7 and Hep G2 cells. Understanding the molecular basis for the liver-specific expression of APOBEC-1 in the rat promises new strategies to induce APOBEC-1 expression in the human liver for the reduction of atherogenic lipoprotein levels by hepatic apo B mRNA editing.
载脂蛋白(apo)B的表达可通过mRNA编辑进行调控,这是apo B mRNA中一种独特的转录后碱基变化。编辑后的apo B mRNA的翻译产物apo B - 48并非致动脉粥样硬化的低密度脂蛋白和脂蛋白(a)的前体。在人类和其他多种哺乳动物中,apo B mRNA在肠道中发生编辑,但在肝脏中不发生编辑,肝脏专门分泌含apo B - 100的脂蛋白作为低密度脂蛋白形成的前体。在大鼠、小鼠、狗和马等物种中,apo B mRNA在肝脏中也会发生编辑,导致血浆中低密度脂蛋白水平较低。apo B mRNA的编辑由apo B mRNA编辑酶复合体介导,其中催化亚基APOBEC - 1在没有肝脏编辑的物种的肝脏中不表达。为了解APOBEC - 1肝脏特异性表达以及肝脏apo B mRNA编辑的分子基础,已对大鼠APOBEC - 1基因的表达模式和基因组结构进行了表征。大鼠APOBEC - 1基因包含6个外显子和2个具有不同活性的启动子。大鼠肝脏中APOBEC - 1的表达是由位于上游的启动子导致的,该启动子具有组织特异性外显子使用方式以及由外显子2编码的APOBEC - 1 mRNA 5' - 非翻译区内的可变剪接。除肝脏外,该启动子还可在脾脏、肺、肾、心脏和骨骼肌中诱导APOBEC - 1表达。位于下游的启动子属于一类新的无TATA框启动子,负责APOBEC - 1在肠道中的大量表达。通过使用荧光素酶作为报告基因对转录起始位点进行定位以及对启动子区域进行缺失分析,已确定了两个启动子的调控元件。下游的肠道特异性启动子在 - 1100至 - 500之间含有一个负调控元件,这似乎将其活性限制在肠道中。大鼠APOBEC - 1基因的上游肝脏特异性启动子可在人肝癌HuH - 7和Hep G2细胞中诱导APOBEC - 1表达以及apo B mRNA的编辑。了解大鼠中APOBEC - 1肝脏特异性表达的分子基础有望为在人肝脏中诱导APOBEC - 1表达以通过肝脏apo B mRNA编辑降低致动脉粥样硬化脂蛋白水平提供新策略。